Drug intelligence / Profile preview

zinc di-(dibutyryl lisinate)

Development stage: Unknown
Lead developer: Integrative Skin Science and Research
Modality: Small Molecules
Administration: Topical

Overview

Zinc di-(dibutyryl lisinate) is an experimental topical agent under investigation for its effects on **skin hydration, transepidermal water loss, elasticity**, and the **skin microbiome** in **photoaged skin**. It is formulated as a cream for topical application, and its precise mechanism of action is not fully elucidated, but it is being studied for its impact on biophysical properties of the skin and the cutaneous microbiota. The molecule appears to be a chelate of zinc with a modified lysine derivative (dibutyryl lisinate). It is not found in major pharmaceutical or chemical substance registries, suggesting it is a novel compound primarily in research settings[1][5].

Other names: zinc di-(dibutyryl lisinate)Z-DBL

Beyond the preview

Go deeper on zinc di-(dibutyryl lisinate).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zinc di-(dibutyryl lisinate).

Explore the full profile